Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside…
International business and policy leaders will gather for four days of dialogue, dealmaking and cross-border collaborationNEW YORK, March 31, 2026…
Shareholders approve all board-proposed agenda itemsCumulative voting, electronic general meetings and the revision of the quarterly dividend record date so…
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for…
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is…
NEW ORLEANS, March 29, 2026 (GLOBE NEWSWIRE) -- Medical AI, a company specializing in artificial intelligence-enabled electrocardiogram (ECG) solutions for…
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue…
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin…
Company Announcement no. 05/2026 Annual General Meeting 2026 Copenhagen, March 27, 2026 Annual General Meeting in cBrain A/SWednesday, April 29,…
Annual Report 2025Regulated information 21 March 2026 The board of directors of Financière de Tubize has established the 2025 annual…